ImmunoGen Inc. (IMGN)

9.99
0.13 1.28
NASDAQ : Health Technology
Prev Close 10.12
Open 10.10
Day Low/High 9.73 / 10.19
52 Wk Low/High 3.73 / 13.41
Volume 2.88M
Avg Volume 3.26M
Exchange NASDAQ
Shares Outstanding 132.85M
Market Cap 1.36B
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

ImmunoGen Announces Presentations At AACR Annual Meeting Highlighting Continued Innovation In ADCs

ImmunoGen Announces Presentations At AACR Annual Meeting Highlighting Continued Innovation In ADCs

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that three posters highlighting the Company's expertise in ADCs will be...

Walt Disney Co., RH, Immunogen: 'Mad Money' Lightning Round

Walt Disney Co., RH, Immunogen: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Walt Disney Co., RH, Immunogen, and Advanced Micro Devices.

Tech Bulls Fear China Drop: Cramer's 'Mad Money' Recap (Tuesday 3/13/18)

Tech Bulls Fear China Drop: Cramer's 'Mad Money' Recap (Tuesday 3/13/18)

In the wake of Trump's blocking the Broadcom-Qualcomm deal, Jim Cramer ask if we should be worried that all of tech that wants to be big in China could be under pressure.

ImmunoGen Reports Pipeline Progress And 2017 Operating Results

ImmunoGen Reports Pipeline Progress And 2017 Operating Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent highlights and operating results for the quarter and year ended...

ImmunoGen Announces Webcasts Of Presentations At Upcoming Conferences

ImmunoGen Announces Webcasts Of Presentations At Upcoming Conferences

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming...

ImmunoGen Announces Conference Call To Discuss Its 2017 Operating Results

ImmunoGen Announces Conference Call To Discuss Its 2017 Operating Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.

ImmunoGen Appoints Stuart A. Arbuckle To Board Of Directors

ImmunoGen Appoints Stuart A. Arbuckle To Board Of Directors

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced the appointment of Stuart A.

ImmunoGen Announces First Patient Dosed In Phase 1 Study Of IMGN632 For Hematological Malignancies

ImmunoGen Announces First Patient Dosed In Phase 1 Study Of IMGN632 For Hematological Malignancies

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the first patient has been treated with IMGN632 in a Phase 1...

Interesting IMGN Put And Call Options For February 16th

Interesting IMGN Put And Call Options For February 16th

Investors in ImmunoGen, Inc. saw new options become available this week, for the February 16th expiration.

ImmunoGen Announces Webcast Of Presentation And Q&A At The 36th Annual J.P. Morgan Healthcare Conference

ImmunoGen Announces Webcast Of Presentation And Q&A At The 36th Annual J.P. Morgan Healthcare Conference

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Mark Enyedy, President and CEO, will present at the upcoming 36 th...

Short Interest Moves 13.8% Higher For IMGN

Short Interest Moves 13.8% Higher For IMGN

The most recent short interest data has been released for the 11/30/2017 settlement date, which shows a 1,583,798 share increase in total short interest for ImmunoGen, Inc. , to 13,085,450, an increase of 13.77% since 11/15/2017.

ImmunoGen Presents New Clinical And Preclinical Data At ASH Annual Meeting

ImmunoGen Presents New Clinical And Preclinical Data At ASH Annual Meeting

ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that new data from the Company's ongoing Phase 1 study of IMGN779, a...

First Week Of July 2018 Options Trading For ImmunoGen (IMGN)

First Week Of July 2018 Options Trading For ImmunoGen (IMGN)

Investors in ImmunoGen, Inc. saw new options begin trading this week, for the July 2018 expiration.

ImmunoGen Announces Webcasts Of Presentations At Upcoming Conferences

ImmunoGen Announces Webcasts Of Presentations At Upcoming Conferences

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming...

Stock Futures Hold Higher After U.S. Adds 261,000 in October

Stock Futures Hold Higher After U.S. Adds 261,000 in October

Stock futures hold higher on Friday, Nov. 3, as job growth rebounds in October after hurricanes wreaked havoc with the September number.

ImmunoGen Reports Recent Progress And Third Quarter 2017 Operating Results

ImmunoGen Reports Recent Progress And Third Quarter 2017 Operating Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent highlights and reported financial results for the quarter ended...

Interesting IMGN Put And Call Options For December 15th

Interesting IMGN Put And Call Options For December 15th

Investors in ImmunoGen, Inc. saw new options become available this week, for the December 15th expiration.

ImmunoGen To Present New Data On Novel Antibody-Drug Conjugates At 59th ASH Annual Meeting

ImmunoGen To Present New Data On Novel Antibody-Drug Conjugates At 59th ASH Annual Meeting

ImmunoGen, Inc . (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that three abstracts highlighting two of the Company's experimental ADC...

Oversold Conditions For ImmunoGen (IMGN)

Oversold Conditions For ImmunoGen (IMGN)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

ImmunoGen Announces Conference Call To Discuss Its Third Quarter 2017 Financial Results

ImmunoGen Announces Conference Call To Discuss Its Third Quarter 2017 Financial Results

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.

ImmunoGen Announces Investigational New Drug Application For IMGN632 For Hematological Malignancies Is Active

ImmunoGen Announces Investigational New Drug Application For IMGN632 For Hematological Malignancies Is Active

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the U.

ImmunoGen Announces Closing Of Public Offering Of Common Stock, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares

ImmunoGen Announces Closing Of Public Offering Of Common Stock, Including Full Exercise Of Underwriters' Option To Purchase Additional Shares

ImmunoGen, Inc. (NASDAQ: IMGN) today announced the closing of its previously announced underwritten public offering of 16,675,000 shares of its common stock, including 2,175,000 shares sold pursuant to the underwriters'...

ImmunoGen Announces Pricing Of Public Offering Of Common Stock

ImmunoGen Announces Pricing Of Public Offering Of Common Stock

ImmunoGen, Inc. (NASDAQ: IMGN) today announced the pricing of an underwritten public offering of 14,500,000 shares of its common stock at a price of $6.

ImmunoGen Announces Proposed Public Offering Of Common Stock

ImmunoGen Announces Proposed Public Offering Of Common Stock

ImmunoGen, Inc. (NASDAQ: IMGN) today announced that it intends to offer and sell, subject to market and other conditions, 13,000,000 shares of its common stock in an underwritten public offering.

Short Interest In ImmunoGen Falls 37.5%

Short Interest In ImmunoGen Falls 37.5%

The most recent short interest data has been released for the 09/15/2017 settlement date, which shows a 7,451,259 share decrease in total short interest for ImmunoGen, Inc. , to 12,429,992, a decrease of 37.48% since 08/31/2017.

ImmunoGen Announces Webcasts Of Presentations At Upcoming Conferences

ImmunoGen Announces Webcasts Of Presentations At Upcoming Conferences

ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the following presentations by Company management at upcoming...

ImmunoGen Announces Agreements To Exchange $76.4 Million Of Its 4.50% Convertible Senior Notes Due 2021 For Common Stock

ImmunoGen Announces Agreements To Exchange $76.4 Million Of Its 4.50% Convertible Senior Notes Due 2021 For Common Stock

ImmunoGen, Inc. (NASDAQ:IMGN) ("ImmunoGen" or the "Company") today announced that it has entered into privately negotiated exchange agreements with a limited number of holders of its 4.

ImmunoGen Reaches Analyst Target Price

ImmunoGen Reaches Analyst Target Price

In recent trading, shares of ImmunoGen, Inc. have crossed above the average analyst 12-month target price of $8.00, changing hands for $8.47/share.